FREE SHIPPING on orders over $150
Track My Order Manage Subscription Sign In Contact Us
Back to 5 MIN READ
Clinical Skin Compatibility Evaluation of a Multi-Active Cosmetic Eye Cream

AVL Eye Cream

Clinical Skin Compatibility Evaluation of a Multi-Active Cosmetic Eye Cream

Single-Application Occlusive Patch Test in Sensitive and Normal Skin Cohorts.

Background

Advanced eye contour formulations increasingly integrate complex multi-active systems to support hydration, barrier function, and visible skin quality. The present Eye Cream combines 17 active ingredients together with a full spectrum of 21 amino acids, reflecting a high-density, performance-oriented formulation approach. Such formulation complexity represents modern dermocosmetic innovation. At the same time, responsible development requires structured validation of the finished product to confirm optimal skin compatibility — particularly in the delicate periocular area. The skin surrounding the eyes is thinner and physiologically more reactive than other facial zones. For this reason, compatibility testing under standardized clinical conditions is essential to ensure both performance and tolerance.

Objective

Two independent monocentric, simple-blind patch test studies were conducted under dermatological supervision at an independent external clinical investigation center. The product was applied pure (undiluted) under 48-hour occlusion using an occlusive Finn Chamber® system (8 mm / 50 mm²). Irritation potential was quantified using the Mean Cumulative Irritation Index (M.C.I.I.), calculated based on standardized erythema and oedema scoring at defined timepoints (30 minutes and 24 hours post-removal).

Methods

Two independent monocentric, simple-blind patch test studies were conducted under dermatological supervision at an external clinical investigation center. The product was applied pure (undiluted) under 48-hour occlusion. Irritation was quantified using the Mean Cumulative Irritation Index (M.C.I.I.).

Results

The eye cream demonstrated M.C.I.I. values of 0.05 (sensitive skin cohort, n=54) and 0.04 (normal skin cohort, n=54), both classified as Non-irritating (<0.25). Across a total of 109 analyzed adult subjects, the product consistently met the Non-irritating classification threshold under standardized occlusive conditions.

Conclusion

Under standardized high-challenge 48-hour occlusive patch-test conditions with pure product application, the complex multi-active Eye Cream — containing 17 active ingredients and 21 amino acids — exhibited excellent skin compatibility in both sensitive and normal skin cohorts.
These findings support its suitability for routine cosmetic use, including application in the delicate periocular area.

Introduction

Skincare formulas are getting more complex

Modern dermocosmetic formulations increasingly combine multiple active ingredients to enhance performance. However, combining numerous bioactive components - particularly at meaningful concentrations - introduces potential concerns regarding cumulative or synergistic irritation effects.

The scientific question is straightforward
Does increasing formulation complexity proportionally increase irritation risk?

Single-application occlusive patch testing is widely used as a first-line compatibility assessment because it:

  • Standardizes dose, exposure time, and evaluation methodology
  • Creates a controlled high-challenge scenario (48-hour occlusion)
  • Quantifies irritation potential using a validated cumulative index (M.C.I.I.)

This methodology serves as a structured clinical compatibility gate prior to broader consumer-use testing and claim substantiation.

The present publication summarizes two standardized patch test studies of Eye Cream conducted in sensitive and normal skin cohorts.

Materials and methods

Safety Assessment & Application Protocol

Safety Assessment & Application Protocol

Study Design

Type: Single-application occlusive patch test

Design: Monocentric, simple-blind

Supervision: Dermatological control

Setting: Independent external clinical investigation center

Application Protocol

Dose: 20 µL

Product state: Pure (undiluted)

Application system: Occlusive Finn Chamber® (8 mm / 50 mm²)

Exposure duration: 48 hours

Assessment timepoints:

  • 30 minutes post-removal
  • 24 hours post-removal

Outcome Measure

Skin reactions were evaluated according to predefined numerical grading scales for:

  • Erythema (E) — redness

Oedema (O) — swelling

AVL Eye Cream

Skin Compatibilty Results

M.C.I.I. provides a quantitative measure of irritation potential under the specific study conditions

Results chart
Cohorts Age Range Phototypes Subjects M.C.I.I Classification
Sensitive Skin 18–70 I–IV 54 0.05 Non-irritating
Normal Skin 18–70 I–IV 55 0.04 Non-irritating

* Interpretation Scale (Max possible value: 6)

Results data
Results data

* Both cohorts independently met the Non-irritating classification threshold (<0.25).

Regulatory and Ethical Compliance

The studies were conducted:

  • Under dermatological supervision
  • In accordance with the Declaration of Helsinki (1964) and subsequent updates
  • Following ICH E6 (R2) Good Clinical Practice principles
  • Within the framework of Regulation (EC) No 1223/2009 on Cosmetic Products
  • In alignment with Commission Regulation (EU) No 655/2013 (cosmetic claims)
  • Under GDPR compliance (Regulation (EU) 2016/679)
  • Within a documented quality management system consistent with internationally recognized standards (e.g., ISO 9001)

Results Discussion

AVL Eye Cream formulation integrates a diverse active profile, including a full complement of 21 amino acids and multiple botanical and skin-supportive ingredients. Despite this complexity, the product demonstrated very low cumulative irritation values in both normal and sensitive skin cohorts.

The tested Eye Cream integrates 17 active ingredients oncluding:

  • Ferulic Acid
  • Vitamin E (Tocopheryal Acetate)
  • Niacinamide
  • Bifida Ferment Lysate
  • Hamamelis Virginiana Leaf Extract
  • Butyrospermum Parkii Butter
  • Corylus Avellana Seed Oil


Rather than assuming compatibility based on ingredient-level safety, the finished formulation was evaluated under controlled, standardized conditions using a 48-hour occlusive patch-test model — a recognized high-challenge scenario for assessing acute irritation potential.

The observed M.C.I.I. values of 0.05 (sensitive skin) and 0.04 (normal skin) fall well below the 0.25 threshold for Non-irritating classification. These results were consistent across two independent cohorts representing.

Tested at Full Strength

PATCH TESTING IS ONE OF THE CLEANEST FIRST ANSWERS BECAUSE IT:

✓ Pure (Undiluted)
✓ Under Occlusion
✓ Uredefined classification thresholds
✓ Using predefined classification thresholds With quantitative scoring methodology

These Findings demonstrate that formulation complexity, when engineered with precision and balance, can coexist with excellent skin compatibility. The study reinforces a core development principle: Performance and gentleness are not opposing goals they are complementary outcomes of disciplined formulation science.

References

  1. European Parliament & Council. (2009). Regulation (EC) No. 1223/2009 on Cosmetic Products, Official Journal of the European Union. This regulation sets out the legal framework for cosmetic safety assessment in the EU, including requirements for demonstrating product safety prior to market placement.
  2. Scientific Committee on Consumer Safety (SCCS). (2021). Notes of Guidance for the Testing of Cosmetic Ingredients and Their Safety Evaluation (11th Revision, SCCS/1628/21). European Commission. Provides scientific guidance on safety evaluation of cosmetics and ingredients under EU law, including considerations on human data for local effects.
  3. Api, A. M., et al. (2021). Draize human repeat insult patch test (HRIPT): Seven decades of protocols and standardization challenges. Toxicology in Vitro. Highlights variability and historical evolution of HRIPT approaches relevant to skin compatibility assessment.